ARCUTIS BIOTHERAPEUTICS, INC. Earnings Per Share (Basic)
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Earnings Per Share (Basic) of $0.11 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was $0.11.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.09.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $0.14.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was $0.06.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$0.13.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$1.16.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$3.78.
- ARCUTIS BIOTHERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$5.66.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.11 10-Q · filed 2026-08-05 | $0.03 10-Q · filed 2026-08-05 | $0.24 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.30 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.09 10-Q · filed 2026-05-06 | $0.10 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.16 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | $0.14 derived: net income ÷ weighted average shares · filed 2026-04-21 | $0.19 derived: net income ÷ weighted average shares · filed 2026-04-21 | $0.07 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.13 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.06 10-Q · filed 2025-10-28 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.26 10-Q · filed 2025-10-28 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.13 10-Q · filed 2026-08-05 | -$0.32 10-Q · filed 2026-08-05 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.20 10-Q · filed 2026-05-06 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.39 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.16 10-K · filed 2026-02-25 |
| 2024-09-30 | -$0.33 10-Q · filed 2025-10-28 | -$0.76 derived: net income ÷ weighted average shares · filed 2025-10-28 | -$1.08 10-Q · filed 2025-10-28 | -$1.73 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-06-30 | -$0.42 10-Q · filed 2025-08-06 | -$0.75 10-Q · filed 2025-08-06 | -$1.41 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.04 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-03-31 | -$0.32 10-Q · filed 2025-05-06 | -$1.00 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.65 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.66 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.53 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.78 10-K · filed 2026-02-25 |
| 2023-09-30 | -$0.73 10-Q · filed 2024-11-06 | -$1.88 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$3.19 10-Q · filed 2024-11-06 | -$4.37 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-06-30 | -$1.16 10-Q · filed 2024-08-14 | -$2.46 10-Q · filed 2024-08-14 | -$3.64 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$5.50 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-03-31 | -$1.31 10-Q · filed 2024-05-14 | -$2.49 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$4.35 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$5.67 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-12-31 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.04 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$4.37 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$5.66 10-K · filed 2025-02-25 |
| 2022-09-30 | -$1.89 10-Q · filed 2023-11-03 | -$3.23 derived: net income ÷ weighted average shares · filed 2023-11-03 | -$4.52 10-Q · filed 2023-11-03 | -$5.94 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-06-30 | -$1.31 10-Q · filed 2023-08-08 | -$2.58 10-Q · filed 2023-08-08 | -$4.00 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$5.14 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2022-03-31 | -$1.27 10-Q · filed 2023-05-09 | -$2.69 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.83 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$4.67 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2021-12-31 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.56 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$3.40 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$4.18 10-K · filed 2024-02-27 |
| 2021-09-30 | -$1.14 10-Q · filed 2022-11-08 | -$1.98 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$2.75 10-Q · filed 2022-11-08 | -$3.55 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-06-30 | -$0.84 10-Q · filed 2022-08-04 | -$1.60 10-Q · filed 2022-08-04 | -$2.40 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.38 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-03-31 | -$0.76 10-Q · filed 2022-05-05 | -$1.55 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.54 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.47 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$0.79 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.79 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.73 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.80 10-K · filed 2023-02-28 |
| 2020-09-30 | -$1.01 10-Q · filed 2021-11-04 | -$1.95 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$3.06 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$0.94 10-Q · filed 2021-08-05 | -$2.05 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | -$22.78 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |